| Patient | Lorraine Hansberry |
|---|---|
| Date of birth | 1993-05-19 |
| Identifiers | MRN HR-ML034-SYN; SSN (made up) 000-34-7158 |
| Document date | 2026-07-16 |
| Author | Odette Marchetti-Fields, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Watery diarrhea since yesterday, three days after chemotherapy. [S]
Ms. Hansberry called the oncology line on day 4 of her fifth cycle of modified FOLFIRINOX and was seen the same day. The pump was disconnected two days ago and pegfilgrastim given. Since yesterday afternoon she has had six watery stools, two of them overnight, and mild cramping. She took loperamide 4 mg at the first loose stool and 2 mg after each one since, eight tablets in all. Her stools are not pale or greasy as they were before pancrelipase, and there is no blood or black stool. She has had no fever (highest 37.2 °C at home), vomiting, or antibiotics, and no one around her is ill. She feels light-headed when she stands and has been drinking less than usual because of the cramps. She is eating little. Her blood glucose readings at home have been 110 to 150 mg/dL. She was writing every morning last week and wants to be back at her desk by the weekend. She has had no thoughts of self-harm. [S]
| Element | Detail |
|---|---|
| Onset | Yesterday afternoon, on day 3 of cycle 5 |
| Severity | Six watery stools a day above her usual; cramping; no blood |
| Context | Irinotecan late diarrhea is expected two to ten days after a dose; pegfilgrastim given two days ago |
| Treatment so far | Loperamide 4 mg, then 2 mg after each loose stool: eight tablets |
| Associated signs and symptoms | Light-headed on standing; no fever, vomiting, blood, or antibiotic use |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired and light-headed on standing; no fever or chills |
| Gastrointestinal | Positive | Watery diarrhea and cramping; no blood, black stool, or vomiting |
| Genitourinary | Positive | Passing less urine than usual |
| Cardiovascular | Negative | No chest pain or leg swelling |
| Endocrine | Negative | Home glucose 110 to 150 mg/dL; no low readings |
| Psychiatric | Negative | Frustrated at losing writing days; no thoughts of self-harm |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Pantoprazole 40 mg delayed-release oral tablet, one tablet by mouth once daily before breakfast | One tablet daily before breakfast | Oral route | 2026-04-20 | active | S |
| Ferric carboxymaltose 50 mg/mL injection, 750 mg intravenously, two doses one week apart | 750 mg intravenously; two doses one week apart | Intravenous route | 2026-04-24 to 2026-05-01 | completed | S |
| Oxycodone 5 mg oral tablet, one tablet by mouth every 4 hours as needed for pain | One tablet every 4 hours as needed | Oral route | 2026-05-04 | active | S |
| Senna 8.6 mg oral tablet, two tablets by mouth at night while taking oxycodone | Two tablets at night | Oral route | 2026-05-04 | active | S |
| Pancrelipase delayed-release capsule (lipase 36,000 units), two capsules with each meal and one with each snack | Two capsules with each meal, one with each snack | Oral route | 2026-05-04 to 2026-10-05 | completed | S |
| Oxaliplatin 5 mg/mL injection, 135 mg (85 mg/m2) intravenously over 2 hours on day 1 of each 14-day cycle, for six cycles | Day 1 every 14 days for six cycles | Intravenous route | 2026-05-18 to 2026-07-27 | completed | S |
| Irinotecan 20 mg/mL injection, 238 mg (150 mg/m2) intravenously over 90 minutes on day 1 of each 14-day cycle, cycles 1 to 5 | Day 1 every 14 days, cycles 1 to 5 | Intravenous route | 2026-05-18 to 2026-07-13 | completed | S |
| Leucovorin 10 mg/mL injection, 634 mg (400 mg/m2) intravenously over 2 hours on day 1 of each 14-day cycle, for six cycles | Day 1 every 14 days for six cycles | Intravenous route | 2026-05-18 to 2026-07-27 | completed | S |
| Fluorouracil 50 mg/mL injection, 3800 mg (2400 mg/m2) by continuous infusion over 46 hours through the port from day 1 of each 14-day cycle, for six cycles, with no bolus | 46-hour infusion from day 1 every 14 days for six cycles | Intravenous route | 2026-05-18 to 2026-07-29 | completed | S |
| Pegfilgrastim 6 mg/0.6 mL prefilled syringe, 6 mg under the skin on day 3 of each cycle, after the pump is disconnected | 6 mg on day 3 of each cycle | Subcutaneous route | 2026-05-20 to 2026-07-29 | completed | S |
| Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nausea | One tablet every 8 hours as needed | Oral route | 2026-05-18 | active | S |
| Olanzapine 5 mg oral tablet, one tablet by mouth at night on days 1 to 4 of each cycle | One tablet at night on days 1 to 4 | Oral route | 2026-05-18 | active | S |
| Loperamide 2 mg oral capsule, two capsules at the first loose stool, then one after each loose stool, no more than eight a day unless directed | 4 mg at onset, then 2 mg after each loose stool | Oral route | 2026-05-18 | active | S |
| Apixaban 2.5 mg oral tablet, one tablet by mouth twice daily during chemotherapy, stopped three days before surgery | One tablet twice daily | Oral route | 2026-06-29 to 2026-08-21 | completed | S |
| Potassium chloride 20 mEq extended-release tablet, two tablets by mouth today, then one tablet daily for three days | 40 mEq today, then 20 mEq daily for three days | Oral route | 2026-07-16 to 2026-07-19 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-07-16 | Body height | 163 | cm | S |
| 2026-07-16 | Body weight | 53.6 | kg | S |
| 2026-07-16 | Body mass index (BMI) [Ratio] | 20.2 | kg/m2 | S |
| 2026-07-16 | Systolic blood pressure | 98 | mm[Hg] | S |
| 2026-07-16 | Diastolic blood pressure | 62 | mm[Hg] | S |
| 2026-07-16 | Heart rate | 104 | /min | S |
| 2026-07-16 | Respiratory rate | 16 | /min | S |
| 2026-07-16 | Body temperature | 37.1 | Cel | S |
| 2026-07-16 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-07-16 | Hemoglobin [Mass/volume] in Blood | 11 | g/dL | 12-15.5 g/dL | Low | S |
| 2026-07-16 | Leukocytes [#/volume] in Blood by Automated count | 6.2 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-07-16 | Neutrophils [#/volume] in Blood by Automated count | 4.1 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 2026-07-16 | Platelets [#/volume] in Blood by Automated count | 188 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-07-16 | Sodium [Moles/volume] in Serum or Plasma | 134 | mmol/L | 135-145 mmol/L | Low | S |
| 2026-07-16 | Potassium [Moles/volume] in Serum or Plasma | 3.2 | mmol/L | 3.5-5.1 mmol/L | Low | S |
| 2026-07-16 | Creatinine [Mass/volume] in Serum or Plasma | 0.94 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-07-16 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 83 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-07-16 | Glucose [Mass/volume] in Serum or Plasma | 118 | mg/dL | 70-99 mg/dL | High | S |
| 2026-07-16 | Magnesium [Mass/volume] in Serum or Plasma | 1.6 | mg/dL | 1.7-2.2 mg/dL | Low | S |
Vital signs recorded on 2026-07-16; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Tired but alert; weight 53.6 kg, down 1.2 kg from the weight at cycle 4; temperature 37.1 °C |
| Vital signs | Lying 104/66 with pulse 96; standing 96/60 with pulse 112 and light-headedness: orthostatic |
| Head, eyes, ears, nose, and throat | Dry mouth; no mouth sores |
| Abdomen | Soft, mildly tender in the lower abdomen without guarding; active bowel sounds; no distension |
| Skin | Port site clean; no jaundice |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Epigastric pain for about two months, boring through to the back and worse after meals and lying flat, with nausea, early fullness, a loss of 5 kg (8 percent of her weight), and pale, loose stools: an upper abdominal cause such as a bleeding ulcer or a pancreatic or duodenal tumor must be found. Upper endoscopy and pancreas-protocol CT booked this week | resolved | confirmed | R10.13 | S — Synthetic presenting problem anchored to the documented collapse in pain and the account of a suspected duodenal ulcer. Superseded by the diagnosis at the second visit. |
| Iron deficiency anemia from chronic upper gastrointestinal blood loss: black stools on and off for three weeks, two near-fainting spells, hemoglobin 9.1 g/dL, MCV 74 fL, ferritin 6 ng/mL | active | confirmed | D50.0 | S — Synthetic finding anchored to the documented account that she was told she had anemia and bleeding ulcers. |
| New hyperglycemia: A1c 6.6% and random glucose 132 mg/dL in a lean woman of 32 who is losing weight; new diabetes with weight loss can be the first sign of a pancreatic cancer, so it is to be confirmed and explained, not labeled type 2 | resolved | confirmed | R73.09 | S — Synthetic finding; superseded when diabetes due to the pancreatic cancer was recorded at the second visit. |
| Adenocarcinoma of the head of the pancreas, 3.1 cm, invading the duodenum, borderline resectable (tumor contact of more than half the circumference of the superior mesenteric vein, no arterial contact), no distant spread, CA 19-9 486 U/mL after biliary drainage; on EUS-guided biopsy; synthetic modern detail linked to her documented cancer, whose primary site the sources record differently | active | confirmed | C25.0 | S — Synthetic histology, site, stage and course; the sources say she died of cancer and differ on whether it was pancreatic, duodenal, or colonic with spread to the pancreas (R). See sources.md. |
| Diabetes due to the pancreatic cancer (pancreatogenic, type 3c): A1c 6.6% at intake and fasting glucose 141 mg/dL | active | confirmed | E08.9 | S — Synthetic consequence of the synthetic tumor. |
| Exocrine pancreatic insufficiency from obstruction of the pancreatic duct: pale, floating, loose stools after fatty meals and weight loss | active | confirmed | K86.81 | S — Synthetic consequence of the synthetic tumor; diagnosed clinically, as guidance allows in pancreatic cancer. |
| Cancer-related pain in the upper abdomen and back, 6 out of 10, with sleep broken by it | active | confirmed | G89.3 | S — Synthetic symptom of the synthetic tumor. |
| Obstruction of the distal common bile duct by the tumor, relieved by a covered metal stent placed at ERCP | active | confirmed | K83.1 | S — Synthetic consequence of the synthetic tumor. |
| Chemotherapy-induced diarrhea from irinotecan, grade 2 (five to six watery stools a day above her usual), starting on day 3 of cycle 5, with low potassium and magnesium and mild dehydration; no fever, blood or neutropenia; resolved | active | confirmed | K52.1 | S — Synthetic treatment effect; not a historical claim. |
| Oxaliplatin peripheral neuropathy, grade 1: tingling in the fingers and toes in the cold, lasting a few days after each cycle, with mild tingling at the fingertips between cycles; no effect on writing or buttons | active | confirmed | G62.0 | S — Synthetic common effect of oxaliplatin. |
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma (2026); Benson AB 3rd, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 2004;22(14):2918-2926 (PMID 15254061) (2004)
Follow-up: Phone call tomorrow morning and blood test (potassium, magnesium, creatinine) in two days. Cycle 6 as booked if recovered. Next scheduled visit 2026-08-10: after six cycles: restaging CT and CA 19-9, decision for surgery, and preparation for pancreaticoduodenectomy. [S]